...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Carve-Outs
I've never heard of this before but maybe this is how many of you have been thinking in relation to the current proposal. So if a carve-out is in their plan maybe ZCC can do an IPO for ZLtd. If 34.4 million shares go for $5.00/share, ZLtd. will raise $172 million and at a later date they distribute 34.4% = $59 million between the roughly 105 million current Zenith shareholders...is that how it works? You are all apparently way ahead of me and I'm just guessing so I would appreciate a reply from someone...anyone?? Thanks, PVLee
Share
New Message
Please login to post a reply